SCHEMBL4088593

SCHEMBL4088593

CNC(=O)c1cccc(C2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.54
KDM4E B2RXH2 2/20 0.53
PKM P14618 1/20 0.53
MLYCD O95822 1/20 0.50
USP30 Q70CQ3 2/20 0.48
STS P08842 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
GPR119 Q8TDV5 3/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL3 Q96JM7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
JAK2 O60674 2/20 0.46
JAK3 P52333 2/20 0.46
PTK2 Q05397 2/20 0.46
MEN1 O00255 1/20 0.46
SCN9A Q15858 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31706257 0.87 NAMPT (0.53) NAMPTKDM4EPKMSTSMAPT
SCHEMBL3862182 0.87 NAMPT (0.53) NAMPTKDM4EPKMSTSMAPT
SCHEMBL29769962 0.87 KMO (0.55) NAMPTKDM4EPKMUSP30STS
SCHEMBL226123 0.87 KMO (0.55) NAMPTKDM4EPKMUSP30STS
SCHEMBL19293625 0.87 GPR119 (0.55) NAMPTKDM4EPKMSTSMAPT
SCHEMBL20354579 0.85 NAMPT (0.58) NAMPTKDM4EPKMSTSMAPT
SCHEMBL1274282 0.82 TP53 (0.55) NAMPTKDM4EPKMMAPTTHRB
SCHEMBL30673157 0.82 NAMPT (0.54) NAMPTKDM4EPKMSTSMAPT
SCHEMBL1558412 0.82 NAMPT (0.54) NAMPTKDM4EPKMSTSMAPT
SCHEMBL30563607 0.82 GPR119 (0.65) NAMPTKDM4ESTSMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
EP-1778670-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM Pharma A/S (DK) 2007-05-02 EP disclosed
WO-2006010446-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS MCHR1, MCHR2, MC1R NAMPT 3849/4885KDM4E 3078/4885PKM 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.